Integra LifeSciences IART Deferred Revenue Timing Percentage

Deferred Revenue Timing Percentage at other companies

Crane NXT, Inc.CXT

88%+12.0pp

TecnoglassTGLS

100%0.0pp

KadantKAI

80%+14.0pp

Curtiss-WrightCW

90%0.0pp

Otis WorldwideOTIS

75%-15.0pp

TerexTEX

43%-13.0pp

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligationPercentage.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's deferred revenue timing percentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's deferred revenue timing percentage?: Integra LifeSciences (IART) reported deferred revenue timing percentage of 52% in Q1 2026.
How has Integra LifeSciences's deferred revenue timing percentage changed year-over-year?: Integra LifeSciences's deferred revenue timing percentage decreased by 1.9% year-over-year, from 53% to 52%.